Airway Therapeutics Awarded $1.9 Million NIH Grant to Advance Phase 2b/3 Study of Zelpultide Alfa for Prevention of Bronchopulmonary Dysplasia
ATLANTA, Sept. 29, 2026 /PRNewswire/ — Airway Therapeutics, Inc., a late-stage clinical biopharmaceutical company developing novel biologic therapies for respiratory, inflammatory, and infectious diseases, today announced that it has been awarded a
